What Are Anti-Obesity Medications (AOMs)?

Clinician's Perspective:

• Modern anti-obesity medications (AOM) function by modulating central appetite signaling, delaying gastric emptying, or inhibiting lipid absorption in the gastrointestinal tract.

• In Singapore, typical medical criterion for AOM treatment include a Body Mass Index (BMI) of 27.5 or higher in the presence of weight-related comorbidities like Type 2 Diabetes.

• GLP-1 Receptor Agonists: The newest class of pharmacological agents, including Semaglutide and Tirzepatide, mimics endogenous gut hormones to lower the brain’s "weight set point" (the weight the body naturally strives to maintain).

• Depending on the type of medications used, data indicates that patients utilizing these treatments typically achieve a weight reduction of 3% to 20% of their total body mass within the first 12 months of therapy.

• Safety: Different AOMs have different risk profiles. Potential risks include Pancreatitis (inflammation of the pancreas) and Cholelithiasis (gallstones), requiring strict clinical supervision.

• Durability of Results: Research suggests a significant risk of weight regaining upon stopping medications, if not paired with permanent metabolic and lifestyle restructuring.

The clinical management of obesity has transitioned from a focus on caloric restriction to the sophisticated use of Pharmacotherapy (the treatment of medical conditions using prescribed medication). Recent advancements in metabolic science have introduced a range of FDA-approved agents designed to target the physiological drivers of weight gain rather than relying solely on behavioral modification.

How do AOMs work?

Researchers categorize these pharmacological agents based on their site of action. Centralized agents, such as the combination of Bupropion and Naltrexone, target the reward pathways of the brain to mitigate cravings. In contrast, peripheral agents like Orlistat focus on the enzymatic inhibition of lipase, which prevents the absorption of approximately 25% of dietary fat. While Phentermine triggers norepinephrine release to suppress appetite, while Topiramate enhances satiety and reduces cravings through GABA modulation and glutamate antagonism. Together, they create a synergistic effect on caloric intake.

The most significant breakthrough in the field has been the introduction of Incretin Mimetics (medications that mimic natural hormones to stimulate insulin release). These include GLP-1 (Glucagon-Like Peptide-1) and GIP (Gastric Inhibitory Polypeptide) receptor agonists. By mimicking these hormones, drugs like Tirzepatide and Semaglutide increase Postprandial Satiety (the feeling of fullness after eating) and slow Gastric Emptying (the speed at which food leaves the stomach).

Clinical Outcomes

The efficacy of these treatments is well-documented across multiple clinical trials. Typically, most adults can expect a reduction of at least 5% to 10% total body weight loss with conventional AOMs. With the more power incretin analogues like Semaglutide or Tirzepatide, 15% to 20% total body weight loss may be observed. Typically, improvements in metabolic health, such as HbA1c (a three-month average of blood sugar levels) and blood pressure, are observed while patients are on AOMs.

While these figures are promising, the data also highlights the necessity of "chronic" management. Obesity is increasingly viewed by the medical community as a chronic relapsing disease. When Pharmacotherapy is discontinued, the body often experiences Metabolic Adaptation (the biological process where the body slows its metabolism to prevent further weight loss), frequently leading to weight regain.

Risk Profiles and Adverse Events

All pharmacological intervention carry some risk. The clinical data identifies several common side effects, primarily Gastrointestinal (relating to the stomach and intestines) in nature, including nausea, emesis (vomiting), and constipation. Please consult your doctor to find out more about the potential side effects. More severe but rarer complications include:

1. Pancreatitis: Acute inflammation of the pancreas.
2. Nephrolithiasis: The formation of kidney stones, specifically noted with medications like Topiramate.
3. Sarcopenia: The loss of muscle mass and strength, which can occur during rapid weight loss if protein intake and resistance training are neglected.

The clinical decision to initiate treatment involves a rigorous cost-benefit analysis. Physicians evaluate the patient’s existing comorbidities, such as Obstructive Sleep Apnea (a condition where breathing stops and starts during sleep) or Non-Alcoholic Fatty Liver Disease, against the potential side effects of the chosen medication.

The Role of Multidisciplinary Care

Medications are not "silver bullets." They are most effective when utilized as a tool with lifestyle modifications. The highest rates of long-term success are observed in patients who integrate these drugs with significant nutritional restructuring and increased physical activity.